LXRP - Lexaria to Highlight its DehydraTECH(TM) Technology at Four Upcoming Investor Conferences
(TheNewswire)
- Benzinga Global Small CapConference on December 8 th
- LD Micro Main Event on Dec15 th
- H.C. Wainwright BioConnect, heldon Jan 11-14
- Virtual Biotech Showcase, heldon Jan 11-14
Kelowna, British Columbia - TheNewswire - December 7, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) CNSX:LXX.CN) (the“Company” or “Lexaria”), a global innovator in drug deliveryplatforms, announced today that its Chairman& CEO Chris Bunka is scheduled to present at four upcominginvestor conferences in December 2020 and January 2021. The Companywill discuss its recent successful testing of DehydraTECH TM that showedimproved delivery of two classes of drugs currently in use againstHIV/AIDS with potential for use against SARS-CoV-2/COVID-19.
Event : BenzingaGlobal Small Cap Conference
Date : TuesdayDecember 8, 2020
Time : 3:45 PMET
Event : LD MicroMain Event
Date : Dec 15,2020
Time : 11 AM ET
Registration : https://ve.mysequire.com/
Event :H.C. Wainwright BioConnect
Date : Jan11-14, 2021
Registration : https://hcwevents.com/bioconnect/
Event : VirtualBiotech Showcase
Date : Jan11-14, 2021
Registration : https://informaconnect.com/biotech-showcase/
Mr. Bunka will provide an overview on the Company’sproprietary drug delivery technology, DehydraTECH™ as well asplanned initiatives to enhance the Company’s focus on solutionsrelated to the regulated pharmaceutical and medical market segments in2021. He will also discuss the Company’s recent sale of its non-coreassets in preparation for uplisting to a national securitiesexchange.
About Lexaria
Lexaria BioscienceCorp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1 - 2 hours to minutes, and maskunwanted tastes; and is planned to be further evaluated for orallyadministered bioactive molecules, including anti-virals, cannabinoids,vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), andnicotine. Lexaria has licensed DehydraTECH to multiple companiesincluding a world-leading tobacco producer for the development ofsmokeless, oral-based nicotine products and for use in industries thatproduce cannabinoid beverages, edibles, and oral products. Lexariaoperates a licensed in-house research laboratory and holds a robustintellectual property portfolio with 18 patents granted andapproximately 60 patents pending worldwide. For more information,please visit www.lexariabioscience.com .
INVESTOR CONTACT:
Phone: 866-221-3341
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements assuch term is defined under applicable securities laws. Thesestatements may be identified by words such as "anticipate,""if," "believe," "plan,""estimate," "expect," "intend,""may," "could," "should,""will," and other similar expressions. Such forward-lookingstatements in this press release include, but are not limited to,statements by the company relating the Company’s ability to carryout the antiviral research initiatives, receive regulatory approvalsor experience positive effects from any antiviral research or study.Such forward-looking statements are estimates reflecting the Company'sbest judgment based upon current information and involve a number ofrisks and uncertainties, and there can be no assurance that theCompany will actually achieve the plans, intentions, or expectationsdisclosed in these forward-looking statements. As such, you shouldnot place undue reliance on these forward-looking statements. Factorswhich could cause actual results to differ materially from thoseestimated by the Company include, but are not limited to, governmentregulation and regulatory approvals, managing and maintaining growth,the effect of adverse publicity, litigation, competition, scientificdiscovery, the patent application and approval process, potentialadverse effects arising from the testing or use of products utilizingthe DehydraTECH technology, the Company’s ability to maintainexisting collaborations and realize the benefits thereof, and otherfactors which may be identified from time to time in the Company'spublic announcements and periodic filings with the US Securities andExchange Commission on EDGAR. There is no assurance that existingcapital is sufficient for the Company's needs or that it will be ableto raise additional capital. There is no assurance the Company will becapable of developing, marketing, licensing, or selling productscontaining any active ingredient. There is no assurance that anyplanned corporate activity, scientific research or study, businessventure, letter of intent, technology licensing pursuit, patentapplication or allowance, consumer study, or any initiative will bepursued, or if pursued, will be successful. There is no assurance thatany of Lexaria’s postulated uses, benefits, or advantages for thepatented and patent-pending technology will in fact be realized in anymanner or in any part. No statement herein has been evaluated by theFood and Drug Administration (FDA). Lexaria-associated products arenot intended to diagnose, treat, cure or prevent any disease.
Any forward-looking statements contained in this release speak only asof the date hereof, and the Company expressly disclaims any obligationto update any forward-looking statements contained herein, whether asa result of any new information, future events, changed circumstancesor otherwise, except as otherwise required by law.
The CSE has not reviewed and doesnot accept responsibility for the adequacy or accuracy of thisrelease.
Copyright (c) 2020 TheNewswire - All rights reserved.